cc-95266
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 29, 2020 (NCT04674813)
Timeline
Indications
Studied for
Mechanism of action
TNFRSF17 adcc
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06615479 | Phase 3 | Feb 15, 2025 | Bristol-Myers Squibb, Celgene |
| NCT06297226 | Phase 2 | Mar 21, 2024 | Bristol-Myers Squibb |
| NCT06121843 | Phase 1 | Dec 31, 2023 | Bristol-Myers Squibb |
| NCT04674813 | Phase 1 | Dec 29, 2020 | Bristol-Myers Squibb, Juno Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 3 | 3 | 2020 |
| Celgene | For profit | 1 | 0 | 1 | 2025 |
| Juno Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1